Re: Abiraterone and Increased Survival in Metastatic Prostate Cancer

Expert’s summary: This study randomized 1195 patients with disease progression after taxotere chemotherapy for prostate cancer to receive abiraterone plus prednisone or placebo plus prednisone. In a well-balanced randomized group, with median follow-up of 13 mo, overall survival was increased significantly with abiraterone (14.8 mo vs 10.9 mo). Secondary end points such as time to prostate-specific antigen (PSA) progression, progression-free survival, and PSA response were also significantly improved with abiraterone. Side effects such as fluid retention, hypertension, and hypokalemia were more frequently seen in the abiraterone group than the placebo group.